Back to Search
Start Over
Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.
- Source :
-
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2021 Jul; Vol. 26 (29). - Publication Year :
- 2021
-
Abstract
- We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.
- Subjects :
- Adult
Aged
COVID-19 Vaccines
Europe
Humans
Primary Health Care
COVID-19
SARS-CoV-2
Subjects
Details
- Language :
- English
- ISSN :
- 1560-7917
- Volume :
- 26
- Issue :
- 29
- Database :
- MEDLINE
- Journal :
- Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
- Publication Type :
- Academic Journal
- Accession number :
- 34296676
- Full Text :
- https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670